![]() ![]() Adare has developed and manufactured more than 40 products sold by partners in more than 100 countries globally including Lacteol™, Zoolac™, Viactiv™, and a number of branded and complex generic products. Through its specialty contract development and manufacturing organization (CDMO) business, Adare provides co-development and contract services to biopharmaceutical companies worldwide to develop and manufacture products marketed by its partners. The Company utilizes its differentiated pharmaceutical technology and microbiome scientific platforms to develop novel, improved medicines and therapies for the global market. is a clinical-stage pharmaceutical company and leading global provider of advanced pharmaceutical technologies, development and manufacturing. Duane Morris LLP served as legal advisor to Adare in the transaction.Īdare Pharmaceuticals, Inc. Life Science Legal LLC served as general and transaction legal counsel to Orbis while Gunderson Dettmer served as Orbis’ corporate and securities legal counsel. Stifel acted as exclusive financial advisor to Orbis in this transaction. Orbis Biosciences will maintain its operations in Lenexa, KS and integration of the companies will commence immediately. The acquisition was finalized on April 30 th for an undisclosed amount. These technologies are designed to be used together for greater flexibility in designing release profiles. We are pleased to join Adare, an industry leader in drug formulation development and manufacturing.”Īdare’s technologies include: Microcaps® for taste-masking via a solvent or aqueous based coacervation process Diffucaps ® that incorporates release-controlling polymers or protective coatings onto drug-layered cores, granules, or crystals and the MMTS TM Multi Mini Tablet System in which functional membranes are applied to 1.0-2.0 mm cylindrical tablets to control release rates. “Orbis’s focus on precision delivery solutions has enabled us to develop expertise in novel extended-release and pulsatile-release formulations and to collaborate with great partners. “The acquisition by Adare will globalize the reach of our technologies and services,” said Maria Flynn, president and CEO of Orbis Biosciences. Orbis’s proprietary technology includes three platforms: Optimμm ® for oral delivery Stratμm TM for injectable delivery and Unisun ® for otic delivery. The platform technology is flexible and customizable to accommodate a broad range of active ingredients, including small molecules, peptides, and proteins. Its Precision Particle Fabrication ® technology is the only technology currently on the market that can produce uniform particles in size ranges suitable for use in injectable, otic and oral dosage forms. Orbis provides enhanced technologies in a scaled, single-step manufacturing process. ![]() These will broaden our product development offerings and ultimately, advance the growth of our CDMO business, further strengthening our leadership in taste-masking and controlled-release technologies.” “In particular, their platforms create drug particles that can be dosed in oral liquid, injectable, and otic dosage forms. “Orbis’s customized technologies are an excellent complement to our contract development and manufacturing organization (CDMO) business which is currently focused on oral dosage forms for pharmaceutical and OTC medicines,” said John Fraher, CEO of Adare Pharmaceuticals, Inc. ![]() The acquisition of Orbis will enhance Adare’s Pharmaceutical Technologies business, which develops and manufactures products for global pharmaceutical, animal health and over-the-counter (OTC) markets. & LENEXA, Kan.-( BUSINESS WIRE)- Adare Pharmaceuticals, Inc., a clinical-stage pharmaceutical company and leading global provider of advanced pharmaceutical technologies, development and manufacturing, today announced that it has acquired the pharmaceutical technology company, Orbis Biosciences, Inc. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |